Viridian Therapeutics appoints Carrie Melvin as COO, effective June 21, 2022

Viridian Therapeutics, Inc.\DE

Carrie Melvin named COO; previously SVP Clinical Development at X4 Pharmaceuticals (Nasdaq: XFOR).
Base salary $425K, sign-on bonus $60K, target bonus 40% of base salary.
Receives inducement option for 210,000 shares vesting over 4 years (25% at 1-year cliff).
Melvin brings 20+ years experience from GSK, TESARO, and Kura Oncology.
Position is newly created; company advancing late-stage clinical development for TED programs.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carrie Melvin

Chief Operating Officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2022-06-21
Filed: June 23, 2022, 7:59 PM ET

On June 21, 2022, the board of directors of Viridian Therapeutics, Inc. (the “Company”) appointed Carrie Melvin as Chief Operating Officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carrie Melvin was appointed as Chief Operating Officer at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On June 21, 2022, the board of directors of Viridian Therapeutics, Inc. (the “Company”) appointed Carrie Melvin as Chief Operating Officer of the Company, effective immediately.

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-22-179235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.